Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.67 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.67 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.65 |
| ▸ | PTGFR | P43088 | 1/20 | 0.65 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL22633156 | 0.96 | PTGER4 (0.62) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| Diethanolamine SCHEMBL28521337 | 0.94 | PTGER4 (0.60) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL30760662 | 0.90 | PTGER4 (0.66) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL32684932 | 0.90 | PTGER4 (0.67) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL30760666 | 0.90 | PTGER4 (0.66) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL196388 | 0.90 | PTGER4 (0.55) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL30760664 | 0.89 | PTGER4 (0.62) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL24677077 | 0.89 | PTGER4 (0.52) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL27139773 | 0.89 | PTGER4 (0.64) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL30916165 | 0.85 | PTGER4 (0.53) | PTGER4PTGER2PTGDRTBXA2RPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240860-B2 | Heterobicyclic carboxylic acids and salts thereof | Foshan Ionova Biotherapeutics Co., Inc. (CN) | 2025-03-04 | — | — | US | claimed |
| CN-111936502-B | Heterobicyclic carboxylic acids and salts thereof | 深圳市原力生命科学有限公司 | 2024-05-31 | — | — | CN | claimed |
| US-20210079013-A1 | Heterobicyclic Carboxylic Acids and Salts Thereof | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2021-03-18 | — | — | US | claimed |
| EP-3759114-A1 | HETEROBICYCLIC CARBOXYLIC ACIDS AND SALTS THEREOF | Shenzhen Ionova Life Science Co., Ltd. (CN) | 2021-01-06 | — | — | EP | claimed |
| EP-3749323-A1 | HETEROBICYCLIC CARBOXYLIC ACIDS FOR TREATING CANCER OR INFLAMMATORY DISEASES | Shenzhen Ionova Life Science Co., Ltd. (CN) | 2020-12-16 | — | — | EP | claimed |
| CN-111936502-A | Heterobicyclic carboxylic acids and salts thereof | 深圳市原力生命科学有限公司 | 2020-11-13 | — | — | CN | claimed |
| US-20200352906-A1 | Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2020-11-12 | — | — | US | claimed |
| CN-111727044-A | Heterobicyclic carboxylic acids for the treatment of cancer or inflammatory diseases | 深圳市原力生命科学有限公司 | 2020-09-29 | — | — | CN | claimed |
| WO-2019149286-A1 | HETEROBICYCLIC CARBOXYLIC ACIDS FOR TREATING CANCER OR INFLAMMATORY DISEASES | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2019-08-08 | — | — | WO | claimed |
| EP-2320906-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | BETA PHARMA CANADA INC (CA) | 2016-02-24 | — | — | EP | claimed |
| CN-102149384-B | Heterocyclic amide derivatives as EP4 receptor antagonists | NANJING AOZHAO BIOLOG CO LTD | 2014-08-20 | — | — | CN | claimed |
| US-8404736-B2 | Heterocyclic amide derivatives as EP4 receptor antagonists | BETA PHARMA CANADA INC. (CA) | 2013-03-26 | — | — | US | claimed |
| JP-2012500211-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | BETA PHARMA CANADA INC. (CA) | 2011-06-09 | — | — | US | claimed |
| EP-2320906-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Beta Pharma Canada Inc. (CA) | 2011-05-18 | — | — | EP | claimed |
| WO-2010019796-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | CHEMIETEK, LLC (US) | 2010-02-18 | — | — | WO | claimed |
| US-12240860-B2 | Heterobicyclic carboxylic acids and salts thereof | Foshan Ionova Biotherapeutics Co., Inc. (CN) | 2025-03-04 | — | — | US | disclosed |
| CN-111936502-B | Heterobicyclic carboxylic acids and salts thereof | 深圳市原力生命科学有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | BETA PHARMA CANADA INC. (CA) | 2011-06-09 | — | — | US | disclosed |
| WO-2010019796-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | CHEMIETEK, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079013-A1 | Heterobicyclic Carboxylic Acids and Salts Thereof | PTGER4, PTGER1, GPR4 | PTGER4 1/4885PTGER2 9/4885PTGDR 24/4885 |
| US-12240860-B2 | Heterobicyclic carboxylic acids and salts thereof | PTGER4, PTGER1, GPR4 | PTGER4 1/4885PTGER2 9/4885PTGDR 24/4885 |
| US-20200352906-A1 | Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885PTGDR 13/4885 |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885PTGDR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.